Salivary Amylase as a Marker of Salivary Gland Function in Patients Undergoing Radiotherapy for Oral Cancer

V. K.Vaishnavi Vedam, Karen Boaz, Srikant Natarajan, Sivadas Ganapathy

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: The aim of this study was to evaluate salivary amylase in patients with primary oral cancer undergoing radiotherapy as the main modality of treatment. Materials/methods: The study was conducted on ten histologically proven cases of oral cancer undergoing radiotherapy. Stimulated whole saliva was collected at three stages of radiotherapy—0, 3, and 6 weeks. Salivary amylase was estimated using Henry-Chiamori method and comparison was made with appropriate age- and gender-matched controls. Results: Salivary amylase levels showed significant decrease in healthy subjects when compared to oral cancer patients (P < 0.001). The latter group also showed changing trend with initial decrease from 0 to 3 weeks followed by increase from 3 to 6 weeks following radiotherapy (P < 0.0528). Conclusions: The trend in changes in the levels of salivary amylase could be used as a surrogate marker of salivary gland function in patients with oral cancer undergoing radiotherapy as primary treatment.

Original languageEnglish
Article numbere22048
JournalJournal of Clinical Laboratory Analysis
Volume31
Issue number3
DOIs
Publication statusPublished - 01-05-2017

Fingerprint

Mouth Neoplasms
Radiotherapy
Amylases
Salivary Glands
Saliva
Healthy Volunteers
Biomarkers
Therapeutics

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Hematology
  • Public Health, Environmental and Occupational Health
  • Clinical Biochemistry
  • Medical Laboratory Technology
  • Biochemistry, medical
  • Microbiology (medical)

Cite this

@article{d5a69a6883734d789524b96a714b9195,
title = "Salivary Amylase as a Marker of Salivary Gland Function in Patients Undergoing Radiotherapy for Oral Cancer",
abstract = "Background: The aim of this study was to evaluate salivary amylase in patients with primary oral cancer undergoing radiotherapy as the main modality of treatment. Materials/methods: The study was conducted on ten histologically proven cases of oral cancer undergoing radiotherapy. Stimulated whole saliva was collected at three stages of radiotherapy—0, 3, and 6 weeks. Salivary amylase was estimated using Henry-Chiamori method and comparison was made with appropriate age- and gender-matched controls. Results: Salivary amylase levels showed significant decrease in healthy subjects when compared to oral cancer patients (P < 0.001). The latter group also showed changing trend with initial decrease from 0 to 3 weeks followed by increase from 3 to 6 weeks following radiotherapy (P < 0.0528). Conclusions: The trend in changes in the levels of salivary amylase could be used as a surrogate marker of salivary gland function in patients with oral cancer undergoing radiotherapy as primary treatment.",
author = "Vedam, {V. K.Vaishnavi} and Karen Boaz and Srikant Natarajan and Sivadas Ganapathy",
year = "2017",
month = "5",
day = "1",
doi = "10.1002/jcla.22048",
language = "English",
volume = "31",
journal = "Journal of Clinical Laboratory Analysis",
issn = "0887-8013",
publisher = "Wiley-Liss Inc.",
number = "3",

}

Salivary Amylase as a Marker of Salivary Gland Function in Patients Undergoing Radiotherapy for Oral Cancer. / Vedam, V. K.Vaishnavi; Boaz, Karen; Natarajan, Srikant; Ganapathy, Sivadas.

In: Journal of Clinical Laboratory Analysis, Vol. 31, No. 3, e22048, 01.05.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Salivary Amylase as a Marker of Salivary Gland Function in Patients Undergoing Radiotherapy for Oral Cancer

AU - Vedam, V. K.Vaishnavi

AU - Boaz, Karen

AU - Natarajan, Srikant

AU - Ganapathy, Sivadas

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Background: The aim of this study was to evaluate salivary amylase in patients with primary oral cancer undergoing radiotherapy as the main modality of treatment. Materials/methods: The study was conducted on ten histologically proven cases of oral cancer undergoing radiotherapy. Stimulated whole saliva was collected at three stages of radiotherapy—0, 3, and 6 weeks. Salivary amylase was estimated using Henry-Chiamori method and comparison was made with appropriate age- and gender-matched controls. Results: Salivary amylase levels showed significant decrease in healthy subjects when compared to oral cancer patients (P < 0.001). The latter group also showed changing trend with initial decrease from 0 to 3 weeks followed by increase from 3 to 6 weeks following radiotherapy (P < 0.0528). Conclusions: The trend in changes in the levels of salivary amylase could be used as a surrogate marker of salivary gland function in patients with oral cancer undergoing radiotherapy as primary treatment.

AB - Background: The aim of this study was to evaluate salivary amylase in patients with primary oral cancer undergoing radiotherapy as the main modality of treatment. Materials/methods: The study was conducted on ten histologically proven cases of oral cancer undergoing radiotherapy. Stimulated whole saliva was collected at three stages of radiotherapy—0, 3, and 6 weeks. Salivary amylase was estimated using Henry-Chiamori method and comparison was made with appropriate age- and gender-matched controls. Results: Salivary amylase levels showed significant decrease in healthy subjects when compared to oral cancer patients (P < 0.001). The latter group also showed changing trend with initial decrease from 0 to 3 weeks followed by increase from 3 to 6 weeks following radiotherapy (P < 0.0528). Conclusions: The trend in changes in the levels of salivary amylase could be used as a surrogate marker of salivary gland function in patients with oral cancer undergoing radiotherapy as primary treatment.

UR - http://www.scopus.com/inward/record.url?scp=84987818143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987818143&partnerID=8YFLogxK

U2 - 10.1002/jcla.22048

DO - 10.1002/jcla.22048

M3 - Article

C2 - 27637993

AN - SCOPUS:84987818143

VL - 31

JO - Journal of Clinical Laboratory Analysis

JF - Journal of Clinical Laboratory Analysis

SN - 0887-8013

IS - 3

M1 - e22048

ER -